Since early 2025, the Trump administration’s sweeping import duties have reshaped global trade flows. But they haven’t triggered a surge in US insolvencies - for now. In this episode, we look at the outlook for business insolvencies in the US and around the world, and the looming risks, from the AI boom and slow growth to financial conditions and fiscal disc ... Show More
Nov 21
Old trade routes for new trade wars?
Can old trade routes adapt to new trade wars? In a world divided by geopolitics, protectionism and the effects of climate change, global trade is forging new paths. In this episode, our AI Assistant Aria explains how commerce is increasingly taking place between geopolitically al ... Show More
4m 36s
Oct 10
Quarterly Outlook Update 2025-27: 10 Top-of-Mind Questions, Answered
We're back with a new episode of Tomorrow, with Allianz Research's AI Assistant Aria! Have you been wondering who is really paying the price of the trade war? Or how companies are managing persistently high financing costs? Well you’re in luck, because our latest global economic ... Show More
4m 49s
Aug 5
The FDA Boss on the Agency’s MAHA Makeover
Dr. Marty Makary has criticized the Food and Drug Administration for being "captured" by Big Food and Big Pharma. Now, the surgeon and former professor is in charge. In an interview with host Jessica Mendoza, the new FDA head talks about food dyes, AI, vaccines and the big change ... Show More
21m 7s
Jun 2023
101: Biotechnology and Healthcare: A New Dawn? With Bob Bradway, CEO of Amgen
The late Steve Jobs of Apple said “I think the biggest innovation of the 21st century will be at the intersection of biology and technology, a new era is beginning”.
If you want see how biotech can change the world of health, whilst potentially being capable of creating extraordi ... Show More
39m 55s
Jul 2025
ICYMI: AstraZeneca Profit, Revenue Lifted by Cancer Drugs
AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer medicines and growth in the US.Revenue climbed 12% to $14.5 billion, the UK drugmaker said Tuesday, beating estimates. Earnings per share excluding some i ... Show More
14m 39s
Apr 2024
Can WeightWatchers survive the Wegovy era?
<p>WeightWatchers is struggling. Launched in the early 1960s, the brand grew by helping members shed pounds through behavioural change programmes. Then, GLP-1 anti-obesity drugs hit the market, long-time spokesperson and board member Oprah Winfrey announced her departure, and the ... Show More
17m 23s